Stramsen Biotech Inc., a plant-based biotechnology company, has announced the submission of its Pre-Investigational New Drug (Pre-IND) package to the U.S. Food and Drug Administration (FDA) for SBX1977, an innovative topical wound care drug. Along with the submission, the company has requested a Pre-IND meeting scheduled for September 16, 2025, and is seeking FDA guidance on advancing directly to Phase 2 clinical trials.
Science Significance
SBX1977 is a standardized plant-based gel enriched with bioactive phytochemicals designed to treat acute and chronic wounds, including diabetic ulcers. Preclinical studies have demonstrated antimicrobial activity, cell proliferation, and tissue regeneration while maintaining a favorable safety profile in animal models. With its roots in traditional topical medicine, SBX1977 integrates natural compounds with modern drug development rigor, offering a next-generation wound care solution.
Regulatory Significance
The Pre-IND submission represents a pivotal regulatory milestone for Stramsen Biotech. By leveraging preclinical evidence and historical human use, the company is pursuing an accelerated clinical pathway that could allow SBX1977 to bypass Phase 1 and progress directly into Phase 2 trials. If endorsed by the FDA, this strategy would shorten development timelines and set a precedent for future plant-based therapeutics.
Business Significance
Advertisement
Stramsen Biotech is a venture-backed biotech firm with a pipeline of 33 drug candidates spanning infectious and noninfectious diseases. The SBX1977 program underscores its focus on high-value, plant-based medicines. Successfully advancing SBX1977 into Phase 2 would enhance the company’s clinical portfolio, strengthen investor confidence, and potentially open commercial opportunities in the multibillion-dollar wound care market.
Patients’ Significance
Chronic wounds, especially diabetic ulcers, remain a major burden for patients worldwide. SBX1977’s dual antimicrobial and regenerative profile offers a novel therapeutic option that could accelerate healing, reduce infection risks, and improve patient outcomes. A successful clinical advancement could bring relief to millions living with non-healing wounds.
Policy Significance
The FDA’s decision on whether to permit a Phase 1 waiver will have broader policy implications for plant-based drug development. A favorable ruling could encourage innovation in botanical therapeutics and support regulatory pathways that balance traditional medicine knowledge with modern validation. This may influence healthcare policies promoting safer, faster, and affordable treatments.
Transaction Highlights
Stramsen Biotech Inc. has submitted a Pre-IND package to the U.S. Food and Drug Administration (FDA) for its plant-based wound healing gel, SBX1977. The company has also secured a Pre-IND meeting scheduled for September 16, 2025, where it will seek regulatory guidance on potentially bypassing Phase 1 trials and advancing directly to Phase 2 clinical development. SBX1977 is positioned as a first-in-class, plant-derived therapeutic for both acute and chronic wounds, including diabetic ulcers. The program is part of Stramsen’s broader pipeline of 33 drug candidates targeting infectious and noninfectious diseases. By achieving this regulatory milestone, Stramsen is advancing its mission of delivering innovative, natural, and clinically validated therapies.
Source: Stramsen Biotech Press Release
